Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Can cardiovascular magnetic resonance prompt early cardiovascular/rheumatic treatment in autoimmune rheumatic diseases? Current practice and future perspectives.

Mavrogeni SI, Sfikakis PP, Dimitroulas T, Koutsogeorgopoulou L, Katsifis G, Markousis-Mavrogenis G, Kolovou G, Kitas GD.

Rheumatol Int. 2018 Jun;38(6):949-958. doi: 10.1007/s00296-018-4004-6. Epub 2018 Mar 7. Review.

PMID:
29516170
2.

Cardiovascular magnetic resonance detects silent heart disease missed by echocardiography in systemic lupus erythematosus.

Mavrogeni S, Koutsogeorgopoulou L, Markousis-Mavrogenis G, Bounas A, Tektonidou M, Lliossis SC, Daoussis D, Plastiras S, Karabela G, Stavropoulos E, Katsifis G, Vartela V, Kolovou G.

Lupus. 2018 Apr;27(4):564-571. doi: 10.1177/0961203317731533. Epub 2017 Sep 19.

PMID:
28927316
3.

Silent myocarditis in systemic sclerosis detected by cardiovascular magnetic resonance using Lake Louise criteria.

Mavrogeni S, Koutsogeorgopoulou L, Karabela G, Stavropoulos E, Katsifis G, Raftakis J, Plastiras S, Noutsias M, Markousis-Mavrogenis G, Kolovou G.

BMC Cardiovasc Disord. 2017 Jul 17;17(1):187. doi: 10.1186/s12872-017-0619-x.

4.

Cardiovascular magnetic resonance imaging pattern at the time of diagnosis of treatment naïve patients with connective tissue diseases.

Mavrogeni S, Markousis-Mavrogenis G, Koutsogeorgopoulou L, Dimitroulas T, Bratis K, Kitas GD, Sfikakis P, Tektonidou M, Karabela G, Stavropoulos E, Katsifis G, Boki KA, Kitsiou A, Filaditaki V, Gialafos E, Plastiras S, Vartela V, Kolovou G.

Int J Cardiol. 2017 Jun 1;236:151-156. doi: 10.1016/j.ijcard.2017.01.104. Epub 2017 Feb 1.

PMID:
28185705
5.

Myocardial perfusion in peripheral Raynaud's phenomenon. Evaluation using stress cardiovascular magnetic resonance.

Mavrogeni S, Bratis K, Koutsogeorgopoulou L, Karabela G, Savropoulos E, Katsifis G, Raftakis J, Markousis-Mavrogenis G, Kolovou G.

Int J Cardiol. 2017 Feb 1;228:444-448. doi: 10.1016/j.ijcard.2016.11.242. Epub 2016 Nov 12.

PMID:
27870974
6.

Cardiovascular magnetic resonance in rheumatology: Current status and recommendations for use.

Mavrogeni SI, Kitas GD, Dimitroulas T, Sfikakis PP, Seo P, Gabriel S, Patel AR, Gargani L, Bombardieri S, Matucci-Cerinic M, Lombardi M, Pepe A, Aletras AH, Kolovou G, Miszalski T, van Riel P, Semb A, Gonzalez-Gay MA, Dessein P, Karpouzas G, Puntmann V, Nagel E, Bratis K, Karabela G, Stavropoulos E, Katsifis G, Koutsogeorgopoulou L, van Rossum A, Rademakers F, Pohost G, Lima JA.

Int J Cardiol. 2016 Aug 15;217:135-48. doi: 10.1016/j.ijcard.2016.04.158. Epub 2016 Apr 27. Review.

PMID:
27179903
7.

Pseudo-infarction pattern in diffuse systemic sclerosis. Evaluation using cardiovascular magnetic resonance.

Mavrogeni S, Karabela G, Koutsogeorgopoulou L, Stavropoulos E, Katsifis G, Plastiras SC, Kitas GD, Panopoulos S, Pentazos G, Tzatzaki E, Markousis-Mavrogenis G, Kolovou G, Sfikakis PP.

Int J Cardiol. 2016 Jul 1;214:465-8. doi: 10.1016/j.ijcard.2016.03.235. Epub 2016 Apr 8.

PMID:
27096964
8.

Imaging Patterns of Cardiovascular Involvement in Mixed Connective Tissue Disease Evaluated by Cardiovascular Magnetic Resonance.

Mavrogeni S, Sfikakis PP, Dimitroulas T, Koutsogeorgopoulou L, Karabela G, Katsifis G, Stavropoulos E, Gialafos E, Spiliotis G, Kolovou G, Kitas GD.

Inflamm Allergy Drug Targets. 2015;14(2):111-6.

PMID:
26728774
9.

Cardiac involvement in ANCA (+) and ANCA (-) Churg-Strauss syndrome evaluated by cardiovascular magnetic resonance.

Mavrogeni S, Karabela G, Gialafos E, Stavropoulos E, Spiliotis G, Katsifis G, Kolovou G.

Inflamm Allergy Drug Targets. 2013 Oct;12(5):322-7.

PMID:
23909889
10.

Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis.

Katsifis GE, Rekka S, Moutsopoulos NM, Pillemer S, Wahl SM.

Am J Pathol. 2009 Sep;175(3):1167-77. doi: 10.2353/ajpath.2009.090319. Epub 2009 Aug 21.

11.

Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus.

Vlachoyiannopoulos PG, Toya SP, Katsifis G, Zintzaras E, Tzioufas AG, Moutsopoulos HM.

J Rheumatol. 2008 Sep;35(9):1768-75. Epub 2008 Jul 15.

PMID:
18634157
12.

Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation.

Moutsopoulos NM, Katsifis GE, Angelov N, Leakan RA, Sankar V, Pillemer S, Wahl SM.

Ann Rheum Dis. 2008 Oct;67(10):1437-43. doi: 10.1136/ard.2007.077891. Epub 2008 Jan 15.

PMID:
18198195
13.

T lymphocytes in Sjögren's syndrome: contributors to and regulators of pathophysiology.

Katsifis GE, Moutsopoulos NM, Wahl SM.

Clin Rev Allergy Immunol. 2007 Jun;32(3):252-64. Review.

PMID:
17992592
14.
15.

Evaluation of the association of autoantibodies with mortality in the very elderly: a cohort study.

Ioannidis JP, Katsifis GE, Stavropoulos ED, Manoussakis MN, Moutsopoulos HM.

Rheumatology (Oxford). 2003 Feb;42(2):357-61.

PMID:
12595636
16.

Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus.

Ioannidis JP, Katsifis GE, Tzioufas AG, Moutsopoulos HM.

J Rheumatol. 2002 Oct;29(10):2129-35.

PMID:
12375322
17.

Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus.

Katsifis GE, Tzioufas AG, Vlachoyiannopoulos PG, Voulgarelis M, Moutsopoulos HM, Ioannidis JP.

Rheumatology (Oxford). 2002 Jul;41(7):780-6.

PMID:
12096228
18.

Supplemental Content

Loading ...
Support Center